Other languages Fate Therapeutics, Inc.

Equities

FATE

US31189P1021

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-13 pm EDT			5-day change	1st Jan Change
4.15 ^USD	+1.72%		-1.66%	+10.96%

May. 10	Piper Sandler Adjusts Fate Therapeutics' Price Target to $4 From $7, Keeps Neutral Rating	MT
May. 10	Wedbush Adjusts Fate Therapeutics' Price Target to $5 From $7, Keeps Neutral Rating	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Fate Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09
Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-The-Shelf FT819 CAR T-Cell Program	May. 09
Fate Therapeutics, Inc. Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting	Apr. 22
Fate Therapeutics Prices $100 Million Offering, Private Placement	Mar. 19
Fate Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 26
Fate Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 26
Fate Therapeutics, Inc. Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients with HER2-expressing Advanced Solid Tumors	Jan. 08
Fate Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08
Fate Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08
Yu-Waye Chu Intends to Resign as Chief Medical Officer of Fate Therapeutics, Inc. Effective as of July 14, 2023	23-06-08
Fate Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-03
Fate Therapeutics, Inc. Provides Earnings Guidance for the Year 2023	23-05-03
Fate Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-28
Fate Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-28
BB Biotech bestätigt Verlust für 2022 - Erwartet mehr Aktivität 2023	23-02-17
Century Therapeutics' Pipeline Prioritization Plans Indicate Declining Natural Killer Cell Hype, Chardan Research Says	23-01-06
Top Midday Decliners	23-01-06
December Jobs Report Showing Easing Wage Pressures Lift US Equity Futures	23-01-06
Top Premarket Decliners	23-01-06
Fate Therapeutics, Inc. Expects to Terminate Mark Plavsic as Chief Technical Officer, Effective as of March 6, 2023	23-01-05

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Fate Therapeutics, Inc.

Equities

FATE

US31189P1021

Other languages

Filters